ArticlePloS one2026
Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSC) is strongly associated with systemic corticosteroid use, but the risk following intravitreal steroid injections remains unclear, with limited evidence from isolated case reports. This study evaluated the association between intravitreal steroid injections and CSC development using a dual-approach design with Clinical Data Warehouse (CDW) analysis and choroidal thickness validation. We performed CDW analysis of 2,336 patients receiving intravitreal triamcinolone acetonide or dexamethasone implant over 21 years (April 2003-October 2024), screening for CSC within 6 months post-injection. Additionally, we conducted detailed subfoveal choroidal thickness analysis in 269 eyes (January 2023-October 2024) at baseline, 1, 3, and 6 months post-injection using optical coherence tomography. No confirmed CSC cases occurred in either cohort (0/2,336 patients, 95% CI: 0-0.13%; 0/269 eyes). Contrary to the choroidal thickening characteristic of CSC, both steroid formulations produced significant choroidal thinning at 1 month: dexamethasone implant (227.0 ± 65.4μm to 217.9 ± 62.0μm, p < 0.0001) and triamcinolone acetonide (219.8 ± 78.7μm to 218.6 ± 77.7μm, p < 0.0001). Only 4.9% of eyes showed ≥10% choroidal thickening, and none developed CSC features. Both formulations achieved significant macular edema reduction through 6 months. Intravitreal corticosteroids showed no confirmed CSC cases over two decades with choroidal thinning rather than the thickening characteristic of CSC, suggesting distinct pathophysiological mechanisms and a favorable safety profile regarding CSC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.